Adeona, Intrexon deal
Intrexon's Human Therapeutics Division granted Adeona exclusive, worldwide rights to develop and commercialize a DNA-based therapeutic to treat pulmonary arterial hypertension (PAH). The therapeutic uses Intrexon's UltraVector technology for assembling transgenes and its RheoSwitch Therapeutic System recombinase platform for gene therapy delivery. Adeona will use Intrexon's technologies to develop a therapeutic for continuous in vivo cellular production of prostaglandin synthase (PGIS), an effector enzyme that regulates the production of prostacyclin. According to Adeona, deficiency in prostacyclin production is "strongly implicated in PAH." Adeona will be responsible for preclinical and clinical development and commercialization of candidates, while Intrexon will be responsible for technology discovery efforts and managing IP. The companies will share manufacturing responsibilities. ...